- Home
- GILD vs SNY Comparison
GILD vs SNY Comparison
Compare GILD & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- SNY
- Stock Information
- Founded
- GILD 1987
- SNY 1994
- Country
- GILD United States
- SNY France
- Employees
- GILD N/A
- SNY N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- GILD Health Care
- SNY Health Care
- Exchange
- GILD Nasdaq
- SNY Nasdaq
- Market Cap
- GILD 113.0B
- SNY 120.2B
- IPO Year
- GILD 1992
- SNY N/A
- Fundamental
- Price
- GILD $91.84
- SNY $50.74
- Analyst Decision
- GILD Buy
- SNY Buy
- Analyst Count
- GILD 26
- SNY 2
- Target Price
- GILD $98.17
- SNY $57.50
- AVG Volume (30 Days)
- GILD 6.6M
- SNY 2.3M
- Earning Date
- GILD 02-11-2025
- SNY 01-30-2025
- Dividend Yield
- GILD 3.35%
- SNY 4.01%
- EPS Growth
- GILD N/A
- SNY N/A
- EPS
- GILD 0.10
- SNY 4.00
- Revenue
- GILD $28,299,000,000.00
- SNY $54,031,898,261.00
- Revenue This Year
- GILD $6.50
- SNY $0.88
- Revenue Next Year
- GILD $0.36
- SNY $6.28
- P/E Ratio
- GILD $908.39
- SNY $25.09
- Revenue Growth
- GILD 3.31
- SNY 6.01
- 52 Week Low
- GILD $62.07
- SNY $45.22
- 52 Week High
- GILD $98.90
- SNY $58.97
- Technical
- Relative Strength Index (RSI)
- GILD 51.58
- SNY 63.19
- Support Level
- GILD $90.82
- SNY $47.88
- Resistance Level
- GILD $93.07
- SNY $51.08
- Average True Range (ATR)
- GILD 1.54
- SNY 0.66
- MACD
- GILD -0.03
- SNY 0.29
- Stochastic Oscillator
- GILD 56.28
- SNY 89.67
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.